Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.

Saloustros, Emmanouil; Nikolaou, Michail; Kalbakis, Konstantinos; Polyzos, Aris; Christofillakis, Charalampos; Kentepozidis, Nikolaos; Pistamaltzian, Nikolaos; Kourousis, Charalampos; Vamvakas, Lampros; Georgoulias, Vasilios; Mavroudis, Dimitris

Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.

Saloustros, Emmanouil; Nikolaou, Michail; Kalbakis, Konstantinos; Polyzos, Aris; Christofillakis, Charalampos; Kentepozidis, Nikolaos; Pistamaltzian, Nikolaos; Kourousis, Charalampos; Vamvakas, Lampros; Georgoulias, Vasilios; Mavroudis, Dimitris.

Afiliação

Saloustros E; Oncology Unit, General Hospital of Heraklion 'Venizelio-Pananio', Heraklion, Crete, Greece.
Nikolaou M; Department of Internal Medicine, "Hippokratio" General Hospital of Athens, Athens, Greece.
Kalbakis K; Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Polyzos A; 1st Department of Medicine, Medical School, University of Athens, Laikon General Hospital, Athens, Greece.
Christofillakis C; 401 Army General Hospital, Athens, Greece.
Kentepozidis N; Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Pistamaltzian N; Department of Medical Oncology, "Mitera" Hospital, Athens, Greece.
Kourousis C; General Clinic "IASO", Chania, Crete, Greece.
Vamvakas L; Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Georgoulias V; Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Mavroudis D; Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece. Electronic address: mavrudis@med.uoc.gr.

Clin Breast Cancer ; 18(1): 88-94, 2018 02.

Article em En | MEDLINE | ID: mdl-29153775

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem; Bevacizumab/administração & dosagem; Carboplatina/administração & dosagem; Paclitaxel/administração & dosagem; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Adulto; Idoso; Anemia/induzido quimicamente; Anemia/diagnóstico; Anemia/epidemiologia; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Bevacizumab/efeitos adversos; Carboplatina/efeitos adversos; Diarreia/induzido quimicamente; Diarreia/diagnóstico; Diarreia/epidemiologia; Esquema de Medicação; Feminino; Humanos; Infusões Intravenosas; Pessoa de Meia-Idade; Neutropenia/induzido quimicamente; Neutropenia/diagnóstico; Neutropenia/epidemiologia; Paclitaxel/efeitos adversos; Intervalo Livre de Progressão; Índice de Gravidade de Doença; Trombocitopenia/induzido quimicamente; Trombocitopenia/diagnóstico; Trombocitopenia/epidemiologia; Neoplasias de Mama Triplo Negativas/mortalidade; Neoplasias de Mama Triplo Negativas/patologia

Palavras-chave

Advanced breast cancer; Angiogenesis; Chemotherapy; Platinum; VEGF

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatina / Paclitaxel / Neoplasias de Mama Triplo Negativas / Bevacizumab Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google